Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0ZMRYF)
| ADC Name |
HMBD-501
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
HMBD-501; ENV-501
Click to Show/Hide
|
|||||
| Organization |
Hummingbird Bioscience (Originator);Endeavor BioMedicines
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Anti-HER3 mAb
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (HER3)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Site-specific
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Gastric cancer | ||||
| Pancreatic cancer | ||||
| Lung cancer | ||||
| Melanoma | ||||
| Breast cancer | ||||
| Unspecific solid tumor |